Lenvatinib Mesylate

CHEMBL2105704 Phase 4 Onaylandı Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

523.0 g/mol

LogP

—

Phase

4

The mesylate salt form of lenvatinib, a multi-kinase inhibitor approved for thyroid and liver cancers. It is the pharmaceutical form used in the marketed medication.

Moleküler Ağırlık

523,0000 g/mol

TPSA

178,00 Å²

Terapötik Alanlar

Ovarian Cancer Pancreatic Cancer Thyroid Cancer Lymphoma Breast Cancer Prostate Cancer Leukemia

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D Yapı

SVG PNG

Cite this structure

Embed this structure

SMILES

COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O.CS(=O)(=O)O

InChI

InChI=1S/C21H19ClN4O4.CH4O3S/c1-29-19-10-17-13(9-14(19)20(23)27)18(6-7-24-17)30-12-4-5-16(15(22)8-12)26-21(28)25-11-2-3-11;1-5(2,3)4/h4-11H,2-3H2,1H3,(H2,23,27)(H2,25,26,28);1H3,(H,2,3,4)

Molecular Formula

C22H23ClN4O7S

HBD / HBA

4 / 8

Döndürülebilir Bağlar

6

Ağır Atomlar

35

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Sıkça Sorulan Sorular

The mesylate salt form of lenvatinib, a multi-kinase inhibitor approved for thyroid and liver cancers. It is the pharmaceutical form used in the marketed medication.

Yes, Lenvatinib Mesylate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2105704. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 11237762. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Hasta dostu bilgi mi arıyorsunuz?

Lenvatinib Mesylate PillFYI'da

Yapı

Hızlı Veriler

Formül: C22H23ClN4O7S

Dış Bağlantılar

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Tıbbi Sorumluluk Reddi

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.